For UK healthcare professionals
Bioport TriCombo: a glucosamine, chondroitin and hyaluronate intra-articular injection.
A sterile, viscoelastic solution for intra-articular injection containing N-acetylglucosamine (30 mg/ml), chondroitin sodium sulfate (30 mg/ml) and sodium hyaluronate (16 mg/ml, 3 MDa) in a 2.25 ml pre-filled glass syringe. The hyaluronate and chondroitin sulfate are physically associated through hydrogen bonding; the product is not chemically or irradiation cross-linked.
At a glance
Composition, presentation and schedule.
TriCombo combines glucosamine, as N-acetylglucosamine (NAG), with chondroitin sulfate and hyaluronic acid. Chondroitin sulfate and hyaluronate are glycosaminoglycans (GAGs); the hyaluronate is the lubricating component.1
- Composition
- Per ml: N-acetylglucosamine 30 mg, chondroitin sodium sulfate 30 mg, sodium hyaluronate 16 mg1
- Presentation
- 2.25 ml pre-filled single-use glass syringe1
- Hyaluronate molecular weight
- 3 MDa average1
- Cross-linking
- Physical association between hyaluronate and chondroitin sulfate; not chemically or irradiation cross-linked1
- Schedule
- One syringe per treatment; two treatment cycles per year1
- Indication
- Symptomatic treatment of mild to severe knee osteoarthritis1
In this section
Product, evidence, resources and UK supply.
Product information
Composition, rheology, physical cross-linking, indication, schedule and presentation.
OpenEvidence
The published observational study and the manufacturer’s documents, with direct links.
OpenResources
The manufacturer’s brochure and product page, with a direct link to each.
OpenProfessional FAQ
Short, sourced answers to what clinics ask before a first case.
OpenUK supply
Enquire about supply, ordering and a clinical introduction for your clinic.
Open
References
- 1.Nikovari Bio Tech Oy. Bioport TriCombo product brochure. Manufacturer document, 8 pages, 2025. View source